Massachusetts Eye and Ear

Inaugural Award Poised to Advance Treatment Options for Uveal Melanoma Patients

Retrieved on: 
Friday, February 16, 2024
Uveal melanoma, Liver, Melanoma, Research, Doctor of Philosophy, Schepens Eye Research Institute, HLA, Massachusetts Eye and Ear, MD, FDA, MRF, Friends, Food, CURE, Hope, Eye, Frustration, UM, Patient, Family, Disease, Tebentafusp, Education, Nursing

WASHINGTON , Feb. 16, 2024 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) recently announced the winners of the inaugural CURE OM Options Bring Hope Team Science Award: Bruce Ksander, PhD from the Schepens Eye Research Institute; Rizwan Haq MD, PhD from the Dana-Farber Cancer Institute and Margarete Karg, PhD from Massachusetts Eye and Ear Infirmary. The collaborative research project is titled, "Identification of molecular pathways that drive uveal melanoma metastasis." The goal of the team's research is to determine the main factors that drive uveal melanoma (UM) to spread and specifically target the liver, with the hope that this research may guide the development of effective therapeutic interventions. Uveal melanoma is a type of ocular melanoma (OM) and is the most common type of eye cancer in adults that constitutes around 5 of all melanomas. In about half of all UM cases, the disease will spread to other parts of the body. When this occurs, it is almost always fatal.

Key Points: 
  • The collaborative research project is titled, "Identification of molecular pathways that drive uveal melanoma metastasis."
  • Uveal melanoma is a type of ocular melanoma (OM) and is the most common type of eye cancer in adults that constitutes around 5 of all melanomas.
  • The CURE OM Options Bring Hope Team Science Award intends to support an interdisciplinary research team who is researching treatment options for metastatic UM patients not limited by HLA type.
  • To learn more about the CURE OM Options Bring Hope Team Science Award, read here .

HelpMeSee announces Dr. Bonnie An Henderson as president and CEO

Retrieved on: 
Tuesday, October 10, 2023
Ueltschi, Dartmouth College, Refractive surgery, Society, Defense, Medicine, Tufts University School of Dental Medicine, Visual impairment, Tufts University School of Medicine, Department of Defence, Paratriathlon, Journal, American Society of Cataract and Refractive Surgery, Cataract, Harvard Medical School, Publication, Massachusetts Eye and Ear, Geisel School of Medicine, Journal of Refractive Surgery, Woman, Management, Ophthalmology

JERSEY CITY, N.J., Oct. 10, 2023 /PRNewswire/ -- HelpMeSee, the global mission to end cataract blindness by vastly expanding access to high quality, affordable treatment, has elected Dr. Bonnie An Henderson as its President and CEO effective immediately.

Key Points: 
  • JERSEY CITY, N.J., Oct. 10, 2023 /PRNewswire/ -- HelpMeSee, the global mission to end cataract blindness by vastly expanding access to high quality, affordable treatment, has elected Dr. Bonnie An Henderson as its President and CEO effective immediately.
  • Dr. Henderson is an internationally recognized expert in cataract and refractive surgery, with a distinguished career that includes past presidency of the American Society of Cataract and Refractive Surgery.
  • Dr. Bonnie An Henderson said, "My entire professional career as a cataract surgeon and educator has led me to HelpMeSee.
  • Jim Ueltschi, founder, and chairman of the board of directors at HelpMeSee stated that "We are delighted and flattered that Bonnie is our CEO and President.

HelpMeSee announces Dr. Bonnie Henderson as interim president and CEO

Retrieved on: 
Tuesday, August 15, 2023
Abstract, Tufts University School of Medicine, Refractive surgery, Teaching, Henderson, Cataract, Journal of Refractive Surgery, Visual impairment, Woman, Medicine, Paratriathlon, Dartmouth College, Massachusetts Eye and Ear, Tufts University School of Dental Medicine, American Society of Cataract and Refractive Surgery, Harvard Medical School, Journal, Geisel School of Medicine, Society, Management, Veterinary medicine, Ophthalmology

JERSEY CITY, N.J., Aug. 15, 2023 /PRNewswire/ -- Dr. Bonnie Henderson has been named interim president and CEO of HelpMeSee, a global nonprofit that provides cataract treatment training using its innovative simulation-based training system to vastly increase access to treatment and eradicate cataract blindness.

Key Points: 
  • JERSEY CITY, N.J., Aug. 15, 2023 /PRNewswire/ -- Dr. Bonnie Henderson has been named interim president and CEO of HelpMeSee, a global nonprofit that provides cataract treatment training using its innovative simulation-based training system to vastly increase access to treatment and eradicate cataract blindness.
  • Dr. Henderson, an internationally recognized expert in cataract and refractive surgery, is a past president of the American Society of Cataract and Refractive Surgery and a clinical professor at Tufts University School of Medicine.
  • Her textbook "Essentials of Cataract Surgery" is among the most used textbooks for teaching cataract surgery in the United States.
  • In addition, Dr. Henderson created EnVision Summit, an international ophthalmology meeting to support and empower women leaders in medicine.

Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer

Retrieved on: 
Thursday, August 3, 2023
Parisa, University, University of London, Therapy, Doctor of Philosophy, Smith-Kettlewell Eye Research Institute, AMD, Pharmacovigilance, Retinitis pigmentosa, Quality of life, Geographic atrophy, Hope, Statistics, GA, CMO, King's College Hospital, Gesellschaft mit beschränkter Haftung, Harvard Medical School, Ophthalmology, Novartis, Massachusetts Eye and Ear, Patient, CTX, Schepen, Ear, Pharmaceutical industry, Medical device

MUNICH, Aug. 3, 2023 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately.

Key Points: 
  • MUNICH, Aug. 3, 2023 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately.
  • Dr. Zamiri joins CTx from Graybug Vision, Inc., where she held the position of Chief Medical Officer and was responsible for all clinical, statistics, regulatory and medical affairs activities, successfully completing phase II development of their lead asset for wet age-related macular degeneration.
  • "We are excited to welcome Parisa to the CTx team as CMO," said Dr Rafiq Hasan, Chief Executive Officer.
  • said Dr Parisa Zamiri, Chief Medical Officer.

Usher Syndrome Society Commits Another $500,000 for New Round of Usher Syndrome Research Grants

Retrieved on: 
Thursday, July 20, 2023
Retina, Letter, Usher syndrome, University, Vision Research, Hearing loss, Boston Children's Hospital, USH, Research, Paratriathlon, Karger Publishers, Massachusetts Eye and Ear, Hearing, Weill Cornell Medicine, Hospital, University of Oregon, Ear, Pharmaceutical industry

About the Usher Syndrome SocietyThe USH Society is a non--profit created because of an urgent need to save the sight and hearing of those living with Usher syndrome. Realizing that the two most important ways to accelerate research are educating the public and raising research funds, the USH Society began using photojournalism, film, and educational events to bring Usher syndrome to the forefront of rare diseases. The Usher Syndrome Society is a registered 501(c)3. Visit www.UsherSyndromeSociety.org for more information.

Key Points: 
  • Funded projects will help drive collaborative ear-­‐and-­‐eye Usher syndrome research focused on the discovery pipeline including identification of therapeutic strategies and development of novel therapeutic agents.
  • NEEDHAM, Mass., July 20, 2023 /PRNewswire/ -- The Usher Syndrome Society (USH Society), a non-­‐ profit that uses storytelling through the arts, educational events, and collaboration to raise public awareness and funds for research to find treatments and a cure for Usher syndrome (USH) announces a request for applications for Usher syndrome research grants.
  • The "Usher Syndrome Society Translational Research Grants" are intended to support translational research on Usher syndrome in either Preclinical Research and/or Mechanism-­‐based Therapeutic Development.
  • The USH Society is committed to supporting Usher syndrome research at labs with promising work and specific funding needs that accelerate Usher syndrome research towards treatments and a cure.

Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

Retrieved on: 
Tuesday, June 20, 2023
Laboratory, Drug development, Professional Football Compensation Committee, University, Bureau of Oceans and International Environmental and Scientific Affairs, CSU, Horizon Therapeutics, Abbott Laboratories, Senior advisor, Medication, Champaign–Urbana metropolitan area, Technical Guidelines Development Committee, Harvard Medical School, Massachusetts Eye and Ear, Partner, AbbVie, Risk, Syndrome, Thakeham, Ophthalmology, R, Research, CD117, Therapy, Neurology, Johns Hopkins School of Medicine, Pharmaceutical industry, Upadacitinib, Biochemistry, Jasper

REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper’s Board of Directors. Dr. Brun will also join Jasper’s Research and Development Committee as Chairperson and become a member of Jasper’s Compensation Committee. Concurrently, board member Vishal Kapoor has been appointed to join Jasper’s Audit and Compensation Committees. Additionally, Lawrence Klein, Ph.D., has stepped down from Jasper’s Board of Directors as of June 20, 2023, due to requirements of his recent appointment as a Partner of Versant Ventures.

Key Points: 
  • Dr. Brun will also join Jasper’s Research and Development Committee as Chairperson and become a member of Jasper’s Compensation Committee.
  • Concurrently, board member Vishal Kapoor has been appointed to join Jasper’s Audit and Compensation Committees.
  • Additionally, Lawrence Klein, Ph.D., has stepped down from Jasper’s Board of Directors as of June 20, 2023, due to requirements of his recent appointment as a Partner of Versant Ventures.
  • He was most recently a Senior Advisor to Horizon Therapeutics and Vice President of Scientific Affairs and Head of AbbVie Ventures.

Prevent Blindness Issues Call for Nominations for the 2023 Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Award

Retrieved on: 
Wednesday, January 4, 2023
Eye, School, University, Massachusetts Eye and Ear, Public health, Head, Research, UAB, Ohio Department of Health, Master of Science, FACS, OD, United States Department of Veterans Affairs, Research to Prevent Blindness, New England College, University of Illinois Urbana-Champaign, Veterans' affairs, Visual Science, Illinois Eye and Ear Infirmary, DPA, University college, Visual impairment, MBA, Doctor of Philosophy, Professor, Policy, Ear, Johns Hopkins University, Severe cognitive impairment, Essay, New England College of Optometry, ROP, University of Alabama, Bascom Palmer Eye Institute, UIC, New England, Pharmaceutical industry, Management, Optometry, Ophthalmology, MD, Child, MPH

CHICAGO, Jan. 4, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's oldest volunteer eye health and safety organization, is issuing the call for nominations for the "2023 Jenny Pomeroy Award for Excellence in Vision and Public Health," and the fourth annual "Rising Visionary Award." Both awards will be formally presented at the 12th Annual Prevent Blindness Focus on Eye Health National Summit, on July 12-13, 2023.

Key Points: 
  • Both awards will be formally presented at the 12th Annual Prevent Blindness Focus on Eye Health National Summit, on July 12-13, 2023.
  • The highest honor that Prevent Blindness bestows, the award is a tribute to Jenny Pomeroy, who was the CEO of Prevent Blindness Georgia from 1996 until 2013, and an accomplished leader in advancing public health and policy for vision and eye health issues.
  • The recipient of the 2022 Jenny Pomeroy Award for Excellence in Vision and Public Health was VOSH/International, a volunteer-based organization.
  • For more information on the Prevent Blindness Jenny Pomeroy Award for Excellence in Vision and Public Health, please visit https://preventblindness.org/jenny-pomeroy-award-for-excellence-in-visio... .

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

Retrieved on: 
Thursday, December 15, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fast Track, Therapy, Security (finance), Secondary research, Speech, Frequency, Mass General Brigham, Regenerative medicine, Ageing, Intellectual property, Scripps Research, Cochlea, Noise-induced hearing loss, PCA, Trial of the century, Sound, Science, Patient, Research, MS, Sensorineural hearing loss, Degenerative disease, SNHL, FDA, Hearing loss, COVID-19, Cell, Ear, Breakthrough therapy, Growth, GSK3, Failure, Safety, Massachusetts Eye and Ear, Brain, Hearing, Marketing, Health, Speech perception, Legislation, Massachusetts Institute of Technology, Pharmaceutical industry

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the Companys second hearing restoration candidate for sensorineural hearing loss (SNHL).

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the Companys second hearing restoration candidate for sensorineural hearing loss (SNHL).
  • Advancing FX-345 to the clinic is an exciting milestone as we further our pioneering work to develop regenerative therapeutics for hearing loss.
  • Frequency is also evaluating FX-322, a therapeutic candidate for SNHL, in an ongoing Phase 2b study (FX-322-208).
  • Sensorineural hearing loss is the most common form of hearing loss, typically resulting from damage to sensory hair cells in the cochlea.

Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results

Retrieved on: 
Thursday, November 17, 2022
Health, Science, Pharmaceutical, Research, Clinical Trials, SVP, Marketing, PCA, Hearing loss, Communication studies, Sensorineural hearing loss, Breakthrough therapy, Scripps Research, Security (finance), Medical College of Wisconsin, Massachusetts Institute of Technology, Growth, EST, SNHL, MD, Webcast, Q&A, Ageing, Science, Research, Bias, Doctor of Philosophy, Saint Louis University, Intellectual property, Otorhinolaryngology, COVID-19, Mass General Brigham, Legislation, Health, Degenerative disease, Cochlea, FDA, Fast Track, Failure, Frequency, Therapy, Massachusetts Eye and Ear, Ear, Secondary research, Speech perception, Noise-induced hearing loss, SSM Health, Medicine, Otology, Regenerative medicine, SSM, Regeneration, Patient, Pharmaceutical industry, Management

A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical results anticipated in the first quarter of 2023.

Key Points: 
  • A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical results anticipated in the first quarter of 2023.
  • They will also discuss how a medicine for cochlear regeneration may fit with currently available hearing devices and the clinical significance of speech perception on overall hearing.
  • Kevin Franck, Ph.D., SVP, Strategic Marketing and New Product Planning: Cochlear restoration market development and the demand for new therapeutics.
  • Carl LeBel, Ph.D., Chief Development Officer: FX-322 hearing restoration program and the clinical development path.

Wellish Vision Institute Announces Expansion in Southwest Las Vegas

Retrieved on: 
Thursday, November 24, 2022
LAS, University of Pittsburgh Medical Center, Glaucoma, University, University at Buffalo, Patient, Vision Institute, UCLA, UCL Ear Institute, Ophthalmology, National Institutes of Health Clinical Center, Tran, Moses Austin, Morale, Cornea, Children's Mercy Hospital, University of California, Davis, University of Kansas Medical Center, Cataract, Retina, Duane syndrome, University of Arizona, Business administration, Massachusetts Eye and Ear, Apache, Optometry, Buffalo, University of Texas Southwestern Medical Center, GVHD, University of Washington Department of Global Health, Fort Apache, Harvard University, Master of Business Administration, Hotel, Veterinary medicine, Medical device, Seattle metropolitan area

LAS VEGAS, Nov. 23, 2022 /PRNewswire-PRWeb/ -- Wellish Vision Institute is excited to announce they are expanding into Southwest Las Vegas to better serve patients living in this area of Las Vegas. The practice is located at 6710 South Apache Road. The new practice boasts 7,200 square feet and includes 14 exam rooms, all equipped with same state-of-the-art technology found at the other three Wellish Vision locations.

Key Points: 
  • Wellish Vision Institute is excited to announce they are expanding into Southwest Las Vegas to better serve patients living in this area of Las Vegas.
  • LAS VEGAS, Nov. 23, 2022 /PRNewswire-PRWeb/ -- Wellish Vision Institute is excited to announce they are expanding into Southwest Las Vegas to better serve patients living in this area of Las Vegas.
  • As part of this expansion, Wellish Vision Institute is also excited to announce well-respected ophthalmologist Dr. Andrew Tran and optometrist Dr. Tiffany Nguyen are joining the highly trained eye care team at Wellish Vision.
  • Wellish Vision Institute is one of the leading ophthalmology practices in Las Vegas.